Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review

Laeth L. George, Saarang R. Deshpande, Matthew J. Cortese, Ellen K. Kendall, Asmi Chattaraj, Zunairah Shah, Jianjun Zhao, Faiz Anwer

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Multiple myeloma is the second most common hematologic malignancy and remains incurable. Patients who fail multiple lines of therapy typically have a poor prognosis despite recent advances in myeloma treatment. Chimeric antigen receptor T (CAR T) cell treatment has emerged as a promising therapy for many hematologic malignancies, including recently approved and emerging applications for myeloma treatment. A systematic review of the available clinical trial data for CAR T therapies in multiple myeloma was undertaken. All multiple myeloma trials registered at ClinicalTrials.gov were reviewed and studies mentioning CAR T and studying relapsed/refractory multiple myeloma (R/R MM) were included. PubMed, Google Scholar, and conference proceedings were also reviewed to determine which trials had reported data. Twenty-seven registered clinical trials in humans with published data were identified as of March 10, 2021. The majority of these trials were CAR T cells targeting B-cell maturation antigen (BCMA), and many were Phase I studies. Data demonstrated promising short-term (<12 months) efficacy with low incidence of grade 3 or higher toxicities. CAR T cell therapy in R/R MM remains a promising treatment modality. While one biologic has recently received FDA-approval, the majority of products remain investigational and in early-phase trials. More investigation is needed to determine which CAR T constructs and combination therapies optimize patient outcomes.

Original languageEnglish (US)
Pages (from-to)741-751
Number of pages11
JournalClinical Lymphoma, Myeloma and Leukemia
Volume21
Issue number11
DOIs
StatePublished - Nov 2021
Externally publishedYes

Keywords

  • BCMA
  • CAR T cell therapy
  • Chimeric antigen receptor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review'. Together they form a unique fingerprint.

Cite this